Valuation : Atara Biotherapeutics, Inc.

Market Cap 92.35M 79.5M 74.66M 68.17M 128M 8.79B 129M 885M 344M 4.46B 347M 339M 14.76B P/E 2026 *
-7.61x
P/E 2027 * 7.42x
Enterprise Value 92.35M 79.5M 74.66M 68.17M 128M 8.79B 129M 885M 344M 4.46B 347M 339M 14.76B EV / Sales 2026 *
52.1x
EV / Sales 2027 * 2.26x
Free-Float
84.86%
Yield 2026 *
-
Yield 2027 * -
1 day-3.26%
1 week-5.92%
Current month+6.21%
1 month+6.21%
3 months-13.42%
6 months+64.21%
Current year-50.80%
1 week 8.83
Extreme 8.83
10.02
1 month 7.73
Extreme 7.73
10.02
Current year 3.92
Extreme 3.92
19.14
1 year 3.92
Extreme 3.92
19.14
3 years 3.92
Extreme 3.92
49
5 years 3.92
Extreme 3.92
501
10 years 3.92
Extreme 3.92
1,361.25
Manager TitleAgeSince
Chief Executive Officer 53 2024-09-08
Director of Finance/CFO 61 2026-06-25
Investor Relations Contact - 2023-06-30
Director TitleAgeSince
Director/Board Member 62 2014-02-28
Director/Board Member 66 2015-11-22
Director/Board Member 53 2024-09-08
Date Insider Type Main position Quantity % Market Cap. Importance
8/17/26 Sell

Chief Executive Officer

-5,062 0.0562%
7/22/26
Redmile Group LLC
ExerciceCompany 390,482 4.3338%
5/18/26 Sell

Controller/Auditor

-2,414 0.0284%
Change 5-day change 1-year change 3-year change Capi.($)
-3.26%-5.92%-27.88%-75.62% 92.35M
-1.66%-4.96%+49.84%+88.43% 69.54B
-2.19%+1.32%+44.54%+88.38% 64.97B
-3.57%-4.24%+47.11%+5.60% 26.51B
+2.77%-1.74%-16.16%+456.51% 25.89B
-0.46%-9.94%+0.98%-15.98% 25.64B
-9.71%-0.36%+245.87%+377.68% 20.22B
-1.58%+0.47%+29.35%-19.62% 19.98B
-3.36%-7.58%+9.47%+535.81% 15.69B
+0.35%+0.16%+46.96%+144.04% 13.49B
Average -2.27%-3.85%+43.01%+158.52% 28.2B
Weighted average by Cap. -2.02%-3.50%+48.05%+145.50%

Financials

2026 *2027 *
Net sales 1.77M 1.53M 1.43M 1.31M 2.46M 169M 2.47M 16.99M 6.6M 85.57M 6.65M 6.51M 283M 40.87M 35.18M 33.04M 30.17M 56.61M 3.89B 57.01M 392M 152M 1.97B 153M 150M 6.53B
Net income -17.43M -15.01M -14.09M -12.87M -24.15M -1.66B -24.32M -167M -64.91M -841M -65.42M -64.02M -2.79B 18.32M 15.77M 14.81M 13.53M 25.38M 1.74B 25.56M 176M 68.23M 884M 68.77M 67.29M 2.93B
Net Debt - -
Logo Atara Biotherapeutics, Inc.
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.
Employees
10
Date Price Change Volume
26-08-31 US$8.900 -3.26% 30,241
26-08-28 US$9.200 -0.54% 15,345
26-08-27 US$9.250 -1.39% 26,950
26-08-26 US$9.380 -4.67% 63,749
26-08-25 US$9.840 +4.02% 48,513
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
8.900USD
Average target price
13.67USD
Spread / Average Target
+53.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATRA Stock